Kynurenine Trial in ME/CFS - Bergquist

Sly Saint

Sly Saint

Senior Member (Voting Rights)
STUDY AIM
The purpose of the study is to evaluate whether kynurenine is directly connected to ME/CFS patient symptom severity.
LEAD INVESTIGATORS
  • Jonas Bergquist, MD, PhD, Prof, Director ScD
  • Kumari Ubhayasekhera, PhD
  • Sandy Abujrais. PhD Student
STUDY HYPOTHESIS AND DESCRIPTION

“Those of us working on the IDO metabolic trap hypothesis for ME / CFS are really interested in the study proposed by Dr. Bergquist and his team in Uppsala, and recently funded by OMF. Here’s why:

Suppose that some brain cells in a particular brain nucleus are in the IDO metabolic trap. This means that in those cells the concentration of tryptophan is too high, and the concentration of kynurenine is too low. Supplying an outside source of kynurenine, as Dr. Bergquist proposes, could conceivably solve part of the problem by allowing those brain cells to make the neuroactive metabolites of kynurenine that they cannot make if the metabolic trap has been sprung.

So, the clinical trial might improve symptoms caused by too little kynurenine or too little kynurenic acid, a known neuro-protectant. Dr. Bergquist’s expertly designed clinical trial of kynurenine in ME / CFS to improve brain fog, memory, and headache is both important and timely.”

– Robert Phair, Ph.D. The Metabolic Trap
Click to expand...
further details here
https://www.omf.ngo/2020/08/05/kynurenine-trial-in-me-cfs/
 
Nice. I was under the impression that Stanford would conduct the kynurenine trial and that Berquist et al. would be responsible for the pyridostigmine one, but anyway, I feel more excited about this one. At least this is something new I haven't seen previously attempted unlike with Mestinon.
 
You must log in or register to reply here.
Back
Top Bottom